KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $1.3 billion.

  • Jazz Pharmaceuticals' Cash & Current Investments fell 40.22% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 billion, marking a year-over-year increase of 4.09%. This contributed to the annual value of $2.4 billion for FY2024, which is 60.18% up from last year.
  • Jazz Pharmaceuticals' Cash & Current Investments amounted to $1.3 billion in Q3 2025, which was up 11.45% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Cash & Current Investments peaked at $2.4 billion during Q4 2024, and registered a low of $490.8 million during Q1 2022.
  • Its 3-year average for Cash & Current Investments is $1.6 billion, with a median of $1.4 billion in 2024.
  • In the last 5 years, Jazz Pharmaceuticals' Cash & Current Investments surged by 198.96% in 2021 and then plummeted by 76.60% in 2022.
  • Jazz Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $591.4 million in 2021, then soared by 49.04% to $881.5 million in 2022, then soared by 70.88% to $1.5 billion in 2023, then soared by 60.18% to $2.4 billion in 2024, then plummeted by 40.22% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.9 billion during Q1 2025.